Anakinra for recalcitrant pyoderma gangrenosum

Loading...
Thumbnail Image
Files
ced.14809 (2).pdf(447.33 KB)
Published Version
Date
2021-06-16
Authors
O'Connor, Cathal
Gallagher, Catriona
Hollywood, Aoife
Paul, Lindsay
O'Connell, Michael
Journal Title
Journal ISSN
Volume Title
Publisher
John Wiley & Sons, Inc.
Published Version
Research Projects
Organizational Units
Journal Issue
Abstract
Pyoderma gangrenosum (PG) is an autoinflammatory neutrophilic dermatosis characterized by rapidly enlarging, painful ulcers. Anakinra is a recombinant interleukin-1 (IL-1) receptor antagonist that blocks the activity of IL-1α and IL-1β by competitively inhibiting IL-1 binding to the IL-1 type I receptor. We present a series of two patients with recalcitrant PG, who had limited therapeutic options due to multiple previous treatment failures and multiple co-morbidities, who obtained 100% healing with anakinra. Compared to conventional first-line therapies for PG, the safety profile of anakinra may be preferable for patients with multiple co-morbidities. Further research is needed to assess the safety and efficacy of anakinra for PG.
Description
Keywords
Pyoderma gangrenosum , Anakinra
Citation
O'Connor, C., Gallagher, C., Hollywood, A., Paul, L. and O'Connell, M. (2021) 'Anakinra for recalcitrant pyoderma gangrenosum', Clinical and Experimental Dermatology. doi: 10.1111/ced.14809
Link to publisher’s version